COMPASS Pathways plc (CMPS) is a publicly traded company in the Healthcare sector, operating within the Medical - Care Facilities industry. The company is headquartered in London, United Kingdom. The current CEO is Kabir Kumar Nath.
CMPS has IPO date of 2020-09-18, 166 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $572.67M.
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
